The 12 closest competitors and alternatives to Lighthouse Pharma among drug discovery companies — ranked by similarity to what Lighthouse Pharma actually does, not by market-cap band.
Subscribe to see Lighthouse Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Lighthouse Pharma is a clinical-stage private biopharmaceutical company that specializes in precision medicine approaches targeting major unmet medical needs. The company is headquartered at the Buck Institute for Research on Aging in California.
Lighthouse Pharma is a drug discovery company headquartered in United States. It has raised at least $61.2M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $12M in April 2026. Xcout tracks 1 named person at Lighthouse Pharma, including Casey Lynch (Chief Executive Officer).
At least $61.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12M | 1 named | |
| Series A | $49.2M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Lighthouse Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Similar drug discovery company
Retro Biosciences is a biotechnology research company based in Redwood City, California, that develops therapies targeting aging biology. Its goal is to extend healthy human lifespan by 10 years.
Similar drug discovery company
Retrotope, Inc. is a drug development company headquartered in Los Altos, California, focused on creating therapeutics for degenerative diseases.
Similar drug discovery company
Gero is a biotechnology company headquartered in Singapore with a U.S. subsidiary, combining physics, biology, and artificial intelligence to decode human biology and develop life-changing medicines.
Similar drug discovery company
Aneira Pharma, Inc. is a privately held pharmaceutical company founded in 2008 with its headquarters in San Diego, California.
Similar drug discovery company
Nura Bio Inc. is a privately held biopharmaceutical company headquartered in South San Francisco, California, founded in 2018 to develop novel treatments for neurological diseases.
Similar drug discovery company
Automera is an early-stage biotechnology research company headquartered in Singapore. The company focuses on the development of novel therapeutics through autophagy-based targeted protein degradation.
Similar drug discovery company
AllIn Bio is a drug discovery company headquartered in Woodside, California. The firm is developing a precision-immunology approach designed to treat the root cause of chronic inflammatory diseases.
Similar drug discovery company
Stellate Therapeutics is a pre-clinical stage biotechnology company that develops small molecules produced by human gut bacteria into therapies for neurodegenerative and age-related neurological diseases.
Biopharmaceuticals
Synchronicity Pharma Inc. is a biotechnology research company based in San Francisco, California, focusing on circadian medicine.
Biopharmaceuticals
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Biopharmaceuticals
Altay Therapeutics, Inc. is a biotechnology company founded in 2019 and headquartered in the San Francisco Bay Area, California. The company focuses on developing therapeutics within the biotechnology sector.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Lighthouse Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →